EDMONTON, July 12 /CNW/ - CardioMetabolics Inc., a Canadian biopharmaceutical company, announced today that all approvals have been received authorizing the start of their Phase II “Mini-METRxICS” Clinical Trial, which is aimed at reducing Intensive Care Unit (ICU) stays in geriatric patients undergoing cardiopulmonary bypass surgery. Dr. Ruth Collins-Nakai, CMI’s Chief Medical Officer commented that, “we are excited to start this trial of a drug that has the potential to help such a large number of patients globally. According to the American Heart Association, in the US alone, each year more than 750,000 patients undergo open heart surgical procedures!”
